72.70
price up icon4.33%   3.02
after-market アフターアワーズ: 72.70
loading
前日終値:
$69.68
開ける:
$70.68
24時間の取引高:
2.94M
Relative Volume:
1.33
時価総額:
$12.01B
収益:
$943.38M
当期純損益:
$-380.99M
株価収益率:
-29.47
EPS:
-2.4667
ネットキャッシュフロー:
$-325.67M
1週間 パフォーマンス:
+1.44%
1か月 パフォーマンス:
-10.17%
6か月 パフォーマンス:
+15.45%
1年 パフォーマンス:
+125.29%
1日の値動き範囲:
Value
$70.68
$73.61
1週間の範囲:
Value
$68.90
$73.61
52週間の値動き範囲:
Value
$23.95
$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1114)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
1,402
Name
Twitter
@ionispharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IONS icon
IONS
Ionis Pharmaceuticals Inc
72.70 11.51B 943.38M -380.99M -325.67M -2.4667
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
Mar 25, 2026

IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com India

Mar 25, 2026
pulisher
Mar 25, 2026

IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus

Mar 25, 2026
pulisher
Mar 25, 2026

Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat

Mar 25, 2026
pulisher
Mar 25, 2026

Wolfe Research reiterates Ionis stock rating on pricing strategy - Investing.com

Mar 25, 2026
pulisher
Mar 25, 2026

Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail

Mar 24, 2026
pulisher
Mar 24, 2026

Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn

Mar 24, 2026
pulisher
Mar 24, 2026

When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com

Mar 24, 2026
pulisher
Mar 24, 2026

FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView

Mar 24, 2026
pulisher
Mar 24, 2026

FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada

Mar 24, 2026
pulisher
Mar 24, 2026

Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus

Mar 24, 2026
pulisher
Mar 23, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis Pharma EVP Schneider sells $412k in shares By Investing.com - Investing.com South Africa

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis Pharma EVP Schneider sells $412k in shares - Investing.com

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis gains priority review for zilganersen for Alexander disease - MSN

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - BioSpace

Mar 23, 2026
pulisher
Mar 23, 2026

FDA Prioritizes Review of Ionis Pharmaceuticals' Drug for Alexan - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). - Bitget

Mar 23, 2026
pulisher
Mar 23, 2026

FDA accepts zilganersen application for Alexander disease review - Investing.com

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Mar 23, 2026
pulisher
Mar 22, 2026

Ionis Board Shakeup And Valuation Gap Draw Investor Attention - Yahoo Finance

Mar 22, 2026
pulisher
Mar 20, 2026

Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart

Mar 20, 2026
pulisher
Mar 20, 2026

Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative (NASDAQ:IONS) - Seeking Alpha

Mar 20, 2026
pulisher
Mar 20, 2026

IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS) - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Why Ionis Pharmaceuticals’ (IONS) 2026 catalyst pipeline supported Leerink’s higher target - MSN

Mar 19, 2026
pulisher
Mar 19, 2026

Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Groupama Asset Managment - MarketBeat

Mar 19, 2026
pulisher
Mar 18, 2026

Insider Sell: Elizabeth Hougen Sells 225,220 Shares of Ionis Pha - GuruFocus

Mar 18, 2026
pulisher
Mar 18, 2026

Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative? - simplywall.st

Mar 18, 2026
pulisher
Mar 18, 2026

Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 215,048 Shares of Stock - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,692.12 in Stock - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Ionis Pharmaceuticals (NASDAQ: IONS) CFO sells 225,220 shares after option exercises - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

BlueCrest Capital Management Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Alpine Global Management LLC Acquires 30,463 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Retail Trends: Can Ionis Pharmaceuticals Inc outperform in the next rally2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 17, 2026

Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - National Today

Mar 17, 2026
pulisher
Mar 17, 2026

Goldman Sachs Upgrades Ionis Pharmaceuticals (IONS) - MSN

Mar 17, 2026
pulisher
Mar 16, 2026

IONS (IONS) Form 144 notices proposed resale of 225,200 shares - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Ionis Pharmaceuticals (IONS) Among Most Oversold Healthcare Stocks - GuruFocus

Mar 16, 2026
pulisher
Mar 16, 2026

Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

BlueCrest Capital Management Ltd Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Cinctive Capital Management LP Invests $11.37 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Boone Capital Management LLC Takes $27.34 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Baker BROS. Advisors LP Makes New $37.08 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Mar 15, 2026

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):